Your Fertility Appointment Today to Start Your Family Tomorrow


You are here

Accelerated Cycle Patterns Provide Positive Outlook for the Future of Assisted Reproductive Technology

A blog by Dr. Alan B. Copperman, RMA of New York, November 9, 2015

At Reproductive Medicine Associates of New York, our mission is to help individuals and couples attain their family-building goals, and throughout the past 14 years, our physicians and research teams have had the opportunity to participate in the discovery and enhancement of many exciting new technologies in the world of reproductive medicine. These new advancements combined with our skilled clinical team have brought success to thousands of RMA patients year after year.

Just weeks ago, the American Society for Reproductive Medicine (ASRM) held their 71st annual conference in Baltimore, where physicians and researchers presented the latest findings in the field of reproductive medicine. RMA of New York was proud to share a study titled, “Patient Treatment Journeys, Then and Now: 12 Years of Clinical Progress”, in which we performed an in-depth observation of the period between 2003 and 2014, analyzing data from diagnostic cycles, IVF cycles, egg recipient cycles and non-IVF cycles to identify the trends and progress achieved.

Together with Celmatix, a personalized medicine company that leverages big data and genomics to create solutions for providing greater insight to the treatment of infertility at an individual level, we were able to conduct a comprehensive examination on the outcomes experienced with our patients throughout this time period and assess the value of the various technologies employed to reach these outcomes. Our team concluded that through further clinical expertise combined with the use of advanced assisted reproductive technologies, such as comprehensive chromosomal screening (CCS) which allows physicians to identify healthy, chromosomally normal embryos with >98% accuracy, the time span from our patients’ first consultation to discharge to their obstetrician had decreased from 9.1 months to 5.7 months. Additionally, our patients experienced a significant reduction in the number of multiple gestations (which decreased by 50% over that time period), and a diminished number of miscarriages due to the increased utilization of embryo screening technologies.

These groundbreaking achievements are extremely encouraging for patients, as genomic and personalized medicine is paving the way for achieving the best outcomes for healthy offspring. Use of comprehensive chromosomal screening has enabled our physicians to achieve higher success rates for our patients and achieve successful live birth outcomes faster, as we transfer single screened embryos with confidence. We are now able to streamline the technology of choosing one healthy embryo to implant in order to achieve maximum potential for pregnancy, as we have greater insight on the health and likelihood of implantation. In addition to using PGS to screen for chromosomal copy number, preimplantation genetic diagnosis (PGD) has allowed us to perform targeted testing for genetic mutations such as Cystic Fibrosis, Sickle Cell, and Down syndrome prior to transfer of the embryos.

Our study analysis included the interval between cycles, the cost to achieve live birth, the number of embryos transferred, and the differential outcomes between patients with good prognosis vs poor prognosis. Over the course of this period, we were able to introduce significant cost reductions to our patients due to the shortened time to achieve conception and healthy singleton births.

Our team strives to ensure that patients are rapidly progressing along the journey to parenthood and that the opportunity for achieving conception is optimized through the use of these groundbreaking technologies. We are continuing to conduct scientific investigation in the field of genomic medicine and are optimistic that new technologies combined with patient-focused clinical expertise will continue to improve our patients’ likelihood of delivering healthy babies.

The statistical significance of our findings should be a source of hope and inspiration for those who suffer from infertility, as data-driven decision making and access to scientific advances has translated into more targeted treatments and more rapidly achieved successful outcomes. It is our goal to continue to focus on science and patient care and help our patients achieve their goals even more efficiently and successfully.


Add new comment

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
By submitting this form, you accept the Mollom privacy policy.